肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察(1)
摘 要：目的 观察肾衰宁联合科素亚治疗早期糖尿病肾病(DN)的临床疗效。方法 选取2016年1月～2017年1月我科收治确诊的早期DN患者80例，随机分为实验组和对照组，每组40例。对照组给予饮食宣教、运动、降血糖、调血脂等基础治疗并口服科素亚，实验组在对照组基础上口服肾衰宁片。比较治疗3个月后两组24h U-MA、BUN、Cr变化。结果 实验组治疗总有效率为85.00%，显著高于对照组的65.00%，差异有统计学意义(P<0.05);两组治疗后24h U-MA、BUN、Cr均显著低于治疗前，差异有统计学意义(P<0.05);实验组治疗后24h U-MA、BUN、Cr均显著低于对照组，差异有统计学意义(P<0.05)。结论 在治疗早期糖尿病肾病方面，肾衰宁联合科素亚疗效显著，可减少尿蛋白，降低血尿素氮、血肌酐水平，可在临床大力推广。
关键词：肾衰宁;科素亚;糖尿病肾病
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.05.007
, http://www.100md.com
文章编号：1006-1959(2018)05-0020-03
Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu
CHEN Shu-wen
(Department of Endocrinology，Shanghai Baoshan District Integrated Traditional Chinese and Western Medicine Hospital，Shanghai 201900，China)
Abstract：Objective To observe the clinical effect of Shenshuaining combined with Kosu in the treatment of early diabetic nephropathy.Methods From January 2016 to January 2017，80 patients with early DN were randomly divided into experimental group and control group，40 cases in each group.The control group was given diet education，exercise，hypoglycemia，blood lipids adjustment and so on basic treatment and oral Kosu，the experimental group on the basis of the control group oral Shenshuaining tablets，the 24 h U-MA，BUN，Cr changes of the two groups after 3 months were compared.Results The total effective rate of the experimental group was 85.00%，which was significantly higher than that of the control group 65.00%，the difference was significant(P<0.05)，after two groups of treatment，24h U-MA，BUN，Cr were significantly lower than those before treatment，and the difference was statistically significant(P<0.05);the 24 h U-MA，BUN，Cr of the experimental group was significantly lower than that of the control group after treatment，the difference was statistically significant(P<0.05).Conclusion In the treatment of early diabetic nephropathy， Shenshuaining combined with Kosu has a significant effect，which can reduce urinary protein，blood urea nitrogen and serum creatinine level，and can be popularized in clinical practice.
, 百拇医药
Key words：Shenshuaining;Kosu;Diabetic nephropathy
統计资料显示[1]，目前我国糖尿病发病率已超过10%，还未计算入糖尿病前期患者。糖尿病肾病(diabetic nephropathy，DN)是最常见的微血管并发症之一。在我国，糖尿病肾病是仅次于慢性肾小球肾炎导致终末期肾病的常见病因。DN主要指糖尿病性肾小球硬化，是以血管损害为主的肾小球病变，肾病早期表现为镜下肾体积增大，肾小球滤过率呈高滤过状态，可出现一过性蛋白尿或微量白蛋白尿，如果早期积极干预，可不进展至临床肾病期或延缓肾病的发展。现代医学认为，蛋白尿为心脑血管疾病的独立危险因素。本研究通过观察肾衰宁联合科素亚治疗早期糖尿病肾病的临床疗效，望能为糖尿病肾病患者提供新而有效地早期干预措施。, 百拇医药(陈淑雯)
关键词：肾衰宁;科素亚;糖尿病肾病
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.05.007
, http://www.100md.com
文章编号：1006-1959(2018)05-0020-03
Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu
CHEN Shu-wen
(Department of Endocrinology，Shanghai Baoshan District Integrated Traditional Chinese and Western Medicine Hospital，Shanghai 201900，China)
Abstract：Objective To observe the clinical effect of Shenshuaining combined with Kosu in the treatment of early diabetic nephropathy.Methods From January 2016 to January 2017，80 patients with early DN were randomly divided into experimental group and control group，40 cases in each group.The control group was given diet education，exercise，hypoglycemia，blood lipids adjustment and so on basic treatment and oral Kosu，the experimental group on the basis of the control group oral Shenshuaining tablets，the 24 h U-MA，BUN，Cr changes of the two groups after 3 months were compared.Results The total effective rate of the experimental group was 85.00%，which was significantly higher than that of the control group 65.00%，the difference was significant(P<0.05)，after two groups of treatment，24h U-MA，BUN，Cr were significantly lower than those before treatment，and the difference was statistically significant(P<0.05);the 24 h U-MA，BUN，Cr of the experimental group was significantly lower than that of the control group after treatment，the difference was statistically significant(P<0.05).Conclusion In the treatment of early diabetic nephropathy， Shenshuaining combined with Kosu has a significant effect，which can reduce urinary protein，blood urea nitrogen and serum creatinine level，and can be popularized in clinical practice.
, 百拇医药
Key words：Shenshuaining;Kosu;Diabetic nephropathy
統计资料显示[1]，目前我国糖尿病发病率已超过10%，还未计算入糖尿病前期患者。糖尿病肾病(diabetic nephropathy，DN)是最常见的微血管并发症之一。在我国，糖尿病肾病是仅次于慢性肾小球肾炎导致终末期肾病的常见病因。DN主要指糖尿病性肾小球硬化，是以血管损害为主的肾小球病变，肾病早期表现为镜下肾体积增大，肾小球滤过率呈高滤过状态，可出现一过性蛋白尿或微量白蛋白尿，如果早期积极干预，可不进展至临床肾病期或延缓肾病的发展。现代医学认为，蛋白尿为心脑血管疾病的独立危险因素。本研究通过观察肾衰宁联合科素亚治疗早期糖尿病肾病的临床疗效，望能为糖尿病肾病患者提供新而有效地早期干预措施。, 百拇医药(陈淑雯)